Triagonist for GLP-1r, GIPR, and gcgr
By designing GLP-1R, GIPR and GCGR triple agonist compounds of specific polypeptide sequences, the limitations of existing drugs in weight loss and glucose reduction effects are solved, and better therapeutic effects of metabolic disorders are achieved.
WO2025162423A1 Publication Date: 2025-08-07HANG ZHOU SCIWIND BIOSCIENCES CO LTD +1
9 Cites 2 Cited by
Patent Information
- Application Number
- PCT/CN2025/075383
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-02
- Filing Date
- 2025-01-27
- Publication Date
- 2025-08-07
AI Technical Summary
Technical Problem
The existing GLP-1R/GIPR/GCGR dual-target drugs have limitations in weight loss and glucose reduction effects, and it is difficult to design multiple active peptides, which is difficult to meet clinical needs.
Method used
A GLP-1R, GIPR and GCGR triple agonist compound with a completely new polypeptide sequence is developed, synthesized by chemical or biological methods, containing specific amino acid sequences and connecting fatty acid side chains to Lys residues, improving activity and stability.
Benefits of technology
It has achieved better blood sugar control and weight loss effects, and showed drug performance that is better than the existing three agonists, which is suitable for the treatment of metabolic disorders such as diabetes and obesity.
✦ Generated by Eureka AI based on patent content.
Abstract
A triagonist for GLP-1R, GIPR, and GCGR, which can be used for preventing and / or treating metabolic disorders.
Need to check novelty before this filing date? Find Prior Art